Investors purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading hours on Tuesday. $168.12 million flowed into the stock on the tick-up and $70.13 million flowed out of the stock on the tick-down, for a money net flow of $97.99 million into the stock. Of all companies tracked, Gilead Sciences had the 13th highest net in-flow for the day. Gilead Sciences traded down ($0.78) for the day and closed at $74.35

Several research analysts have recently commented on the stock. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target on the stock. in a research note on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $85.03.

The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The stock has a market cap of $97,121.10, a PE ratio of 7.76, a P/E/G ratio of -1.25 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.75 EPS. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 494,999 shares of company stock valued at $37,404,139. Corporate insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in GILD. BlackRock Inc. lifted its position in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. raised its position in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp raised its position in Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after acquiring an additional 310,607 shares in the last quarter. FMR LLC raised its position in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after acquiring an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp raised its position in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after acquiring an additional 116,780 shares in the last quarter. 75.94% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Traders Buy Shares of Gilead Sciences (GILD) on Weakness” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/traders-buy-shares-of-gilead-sciences-gild-on-weakness/1776380.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.